News for Tonix Pharmaceuticals Hld Stock (TNXP)

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December

GlobeNewsWire • 11/28/23

Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia

GlobeNewsWire • 11/15/23

Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

GlobeNewsWire • 11/13/23

Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights

GlobeNewsWire • 11/09/23

Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

GlobeNewsWire • 11/02/23

Tonix shares sink 29% on discontinued development on depression treatment

Market Watch • 11/01/23

Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder

GlobeNewsWire • 10/31/23

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

GlobeNewsWire • 10/30/23

Tonix Pharmaceuticals expects topline results from migraine prevention study in December

Proactive Investors • 10/26/23

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

GlobeNewsWire • 10/26/23

New Hope for Long COVID Sufferers

Accesswire • 10/25/23

Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe

GlobeNewsWire • 10/19/23

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

GlobeNewsWire • 10/18/23

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

GlobeNewsWire • 10/16/23

Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference

GlobeNewsWire • 10/12/23

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe

GlobeNewsWire • 10/11/23

Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference

GlobeNewsWire • 10/09/23

Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain

GlobeNewsWire • 10/04/23

Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?

InvestorPlace • 09/29/23

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

GlobeNewsWire • 09/29/23

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina's Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Dis

GlobeNewsWire • 09/27/23

Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023

GlobeNewsWire • 09/21/23

Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress

GlobeNewsWire • 09/18/23

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023

GlobeNewsWire • 09/14/23

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox

GlobeNewsWire • 08/21/23